EP1817051 - PHARMACEUTICAL COMPOSITIONS COMPRISING BOTULINUM NEUROTOXIN, A NON IONIC SURFACTANT, SODIUM CHLORIDE AND SUCROSE [Right-click to bookmark this link] | Status | Patent maintained as amended Status updated on 08.03.2024 Database last updated on 22.08.2024 | Most recent event Tooltip | 08.03.2024 | Patent maintained (B2 publication) | published on 10.04.2024 [2024/15] | Applicant(s) | For all designated states Ipsen Biopharm Limited Ash Road, Wrexham Industrial Estate Wrexham LL13 9UF / GB | [2024/15] |
Former [2010/26] | For all designated states Ipsen Biopharm Limited Ash Road, Wrexham Industrial Estate Wrexham LL13 9UF / GB | ||
Former [2009/50] | For all designated states Ipsen Developments Limited 190 Bath Road Slough Berkshire SL1 3XE / GB | ||
Former [2007/33] | For all designated states Ipsen Limited 190 Bath Road Slough Berkshire SL1 3XE / GB | Inventor(s) | 01 /
WEBB, Paul Ipsen Biopharm Unit 9, Ash Road Wrexham Industrial Estate Wrexham LL13 9UF / GB | 02 /
WHITE, Mary Ipsen Biopharm Unit 9, Ash Road Wrexham Industrial Estate Wrexham LL13 9UF / GB | 03 /
PARTINGTON, Julie Ipsen Biopharm Unit 9, Ash Road Wrexham Industrial Estate Wrexham LL13 9UF / GB | [2014/42] |
Former [2007/33] | 01 /
WEBB, Paul, Ipsen Biopharm Unit 9, Ash Road, Wrexham Industrial Estate Wrexham LL13 9UF / GB | ||
02 /
WHITE, Mary, Ipsen Biopharm Unit 9, Ash Road, Wrexham Industrial Estate Wrexham LL13 9UF / GB | |||
03 /
PARTINGTON, Julie, Ipsen Biopharm Unit 9, Ash Raod, Wrexham Industrial Estate Wrexham LL13 9UF / GB | Representative(s) | Plasseraud IP 104 Rue de Richelieu CS92104 75080 Paris Cedex 02 / FR | [N/P] |
Former [2024/15] | Plasseraud IP 66, rue de la Chaussée d'Antin 75440 Paris Cedex 09 / FR | ||
Former [2009/50] | Retzler, Charlotte, et al Ipsen Pharma Direction Propriété Intellectuelle 65, quai Georges Gorse 92650 Boulogne Billancourt Cedex / FR | ||
Former [2007/33] | Davies, Jonathan Mark Reddie & Grose 16 Theobalds Road London WC1X 8PL / GB | Application number, filing date | 05757842.9 | 06.07.2005 | [2007/33] | WO2005GB02653 | Priority number, date | GB20040015491 | 12.07.2004 Original published format: GB 0415491 | [2007/33] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | WO2006005910 | Date: | 19.01.2006 | Language: | EN | [2006/03] | Type: | A2 Application without search report | No.: | EP1817051 | Date: | 15.08.2007 | Language: | EN | The application published by WIPO in one of the EPO official languages on 19.01.2006 takes the place of the publication of the European patent application. | [2007/33] | Type: | B1 Patent specification | No.: | EP1817051 | Date: | 25.02.2015 | Language: | EN | [2015/09] | Type: | B2 New European patent specification | No.: | EP1817051 | Date: | 10.04.2024 | Language: | EN | [2024/15] | Search report(s) | International search report - published on: | EP | 14.09.2006 | Classification | IPC: | A61K38/48, A61K47/30 | [2007/33] | CPC: |
A61K9/0019 (EP,US);
A61K38/4886 (EP,US);
A61K38/4893 (EP,US);
A61K47/02 (US);
A61K47/183 (US);
A61K47/22 (US);
A61K47/26 (EP,US);
A61K9/19 (EP,US);
A61P1/00 (EP);
A61P11/00 (EP);
A61P13/00 (EP);
A61P13/02 (EP);
A61P15/00 (EP);
A61P17/00 (EP,US);
A61P17/02 (EP);
A61P19/02 (EP);
A61P21/00 (EP);
A61P21/02 (EP);
A61P25/00 (EP);
A61P25/04 (EP);
A61P25/06 (EP);
A61P25/08 (EP);
A61P25/16 (EP);
A61P27/02 (EP);
A61P29/00 (EP);
A61P3/04 (EP);
A61P3/10 (EP);
A61P35/00 (EP);
A61P37/06 (EP);
A61P5/00 (EP);
| C-Set: |
A61K38/4886, A61K2300/00 (EP);
A61K38/4893, A61K47/26 (US) | Designated contracting states | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR [2024/15] |
Former [2007/33] | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR | Extension states | AL | 09.02.2007 | HR | 09.02.2007 | MK | 09.02.2007 | YU | 09.02.2007 | Title | German: | PHARMAZEUTISCHE ZUSAMMENSETZUNG, ENTHALTEND BOTULINUM NEUROTOXIN, EIN NICHTIONISCHES TENSID, NATRIUMCHLORID UND SACCHAROSE | [2014/30] | English: | PHARMACEUTICAL COMPOSITIONS COMPRISING BOTULINUM NEUROTOXIN, A NON IONIC SURFACTANT, SODIUM CHLORIDE AND SUCROSE | [2007/33] | French: | COMPOSITION PHARMACEUTIQUE CONTENANT DE LA NEUROTOXINE BOTULIQUE | [2007/33] |
Former [2007/33] | PHARMAZEUTISCHE ZUSAMMENSETZUNGEN MIT BOTULINUM NEUROTOXIN, EINEM NICHTIONISCHEN TENSID, NATRIUMCHLORID UND SACCHAROSE | Entry into regional phase | 09.02.2007 | National basic fee paid | 09.02.2007 | Designation fee(s) paid | 09.02.2007 | Examination fee paid | Examination procedure | 13.06.2006 | Request for preliminary examination filed International Preliminary Examining Authority: EP | 09.02.2007 | Examination requested [2007/33] | 08.05.2008 | Despatch of a communication from the examining division (Time limit: M04) | 08.09.2008 | Reply to a communication from the examining division | 09.02.2012 | Despatch of a communication from the examining division (Time limit: M04) | 18.06.2012 | Reply to a communication from the examining division | 25.04.2013 | Despatch of a communication from the examining division (Time limit: M04) | 03.09.2013 | Reply to a communication from the examining division | 26.11.2013 | Despatch of a communication from the examining division (Time limit: M04) | 07.03.2014 | Reply to a communication from the examining division | 23.09.2014 | Communication of intention to grant the patent | 09.01.2015 | Fee for grant paid | 09.01.2015 | Fee for publishing/printing paid | 09.01.2015 | Receipt of the translation of the claim(s) | Divisional application(s) | EP10010686.3 / EP2269631 | EP15000178.2 / EP2939688 | EP18185827.5 / EP3446701 | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 08.05.2008 | Opposition(s) | Opponent(s) | 01
20.11.2015
25.11.2015
ADMISSIBLE Merz Pharma GmbH & Co. KGaA Eckenheimer Landstrasse 100 60318 Frankfurt/Main / DE Opponent's representative Graf Keyserlingk, Nikolai Merz Therapeutics GmbH Patent Affairs Eckenheimer Landstraße 100 60318 Frankfurt am Main / DE | 02
24.11.2015
01.12.2015
ADMISSIBLE ALLERGAN, INC. 2525 Dupont Drive Irvine CA 92612 / US Opponent's representative Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München / DE | 03
24.11.2015
04.12.2015
ADMISSIBLE Daewoong Pharmaceutical Co., Ltd. Bongeunsa-ro 114-gil 12 Gangnam-gu Seoul / KR Opponent's representative Kraus & Lederer PartGmbB Thomas-Wimmer-Ring 15 80539 München / DE | [N/P] |
Former [2024/03] | |||
Opponent(s) | 01
20.11.2015
25.11.2015
ADMISSIBLE Merz Pharma GmbH & Co. KGaA Eckenheimer Landstrasse 100 60318 Frankfurt/Main / DE Opponent's representative Graf Keyserlingk, Nikolai Merz Therapeutics GmbH Patent Affairs Eckenheimer Landstraße 100 60318 Frankfurt am Main / DE | ||
02
24.11.2015
01.12.2015
ADMISSIBLE ALLERGAN, INC. 2525 Dupont Drive Irvine CA 92612 / US Opponent's representative Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München / DE | |||
03
24.11.2015
04.12.2015
ADMISSIBLE Daewoong Pharmaceutical Co., Ltd. Bongeunsa-ro 114-gil 12 Gangnam-gu Seoul / KR Opponent's representative Kraus & Weisert Patentanwälte PartGmbB Thomas-Wimmer-Ring 15 80539 München / DE | |||
Former [2022/28] | |||
Opponent(s) | 01
20.11.2015
25.11.2015
ADMISSIBLE Merz Pharma GmbH & Co. KGaA Eckenheimer Landstrasse 100 60318 Frankfurt/Main / DE Opponent's representative Graf Keyserlingk, Nikolai Merz Therapeutics GmbH Patent Affairs Eckenheimer Landstraße 100 60318 Frankfurt am Main / DE | ||
02
24.11.2015
01.12.2015
ADMISSIBLE ALLERGAN, INC. 2525 Dupont Drive Irvine CA 92612 / US Opponent's representative Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München / DE | |||
03
24.11.2015
04.12.2015
ADMISSIBLE Daewoong Pharmaceutical Co., Ltd. Bongeunsa-ro 114-gil 12 Gangnam-gu Seoul / KR Opponent's representative Ladendorf, Oliver Kraus & Weisert Patentanwälte PartGmbB Thomas-Wimmer-Ring 15 80539 München / DE | |||
Former [2016/01] | |||
Opponent(s) | 01
20.11.2015
25.11.2015
ADMISSIBLE Merz Pharma GmbH & Co. KGaA Eckenheimer Landstrasse 100 60318 Frankfurt/Main / DE Opponent's representative Graf Keyserlingk, Nikolai Merz Pharma GmbH & Co. KGaA Patent Affairs Eckenheimer Landstraße 100 60318 Frankfurt am Main / DE | ||
02
24.11.2015
01.12.2015
ADMISSIBLE ALLERGAN, INC. 2525 Dupont Drive Irvine CA 92612 / US Opponent's representative Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München / DE | |||
03
24.11.2015
ADMISSIBLE Daewoong Pharmaceutical Co., Ltd. Bongeunsa-ro 114-gil 12 Gangnam-gu Seoul / KR Opponent's representative Ladendorf, Oliver Kraus & Weisert Patentanwälte PartGmbB Thomas-Wimmer-Ring 15 80539 München / DE | |||
Former [2016/01] | |||
Opponent(s) | 01
20.11.2015
25.11.2015
ADMISSIBLE Merz Pharma GmbH & Co. KGaA Eckenheimer Landstrasse 100 60318 Frankfurt/Main / DE Opponent's representative Graf Keyserlingk, Nikolai Merz Pharma GmbH & Co. KGaA Patent Affairs Eckenheimer Landstraße 100 60318 Frankfurt am Main / DE | 08.01.2016 | Invitation to proprietor to file observations on the notice of opposition | 09.05.2016 | Reply of patent proprietor to notice(s) of opposition | 25.11.2021 | Despatch of a communication from the opposition division (Time limit: M04) | 15.03.2022 | Reply to a communication from the opposition division | 15.09.2022 | Despatch of a communication from the opposition division (Time limit: M02) | 27.07.2023 | Despatch of interlocutory decision in opposition | 06.08.2023 | Legal effect of interlocutory decision in opposition | 14.11.2023 | Despatch of communication that the patent will be maintained as amended | 02.02.2024 | Fee for printing new specification paid | Appeal following opposition | 26.06.2018 | Appeal received No. T1483/18 | 27.08.2018 | Statement of grounds filed | 18.06.2021 | Result of appeal procedure: maintenance in amended form | 05.08.2021 | Despatch of the decision of the Board of Appeal | 12.06.2018 | Appeal received No. T1483/18 | 27.08.2018 | Statement of grounds filed | 18.06.2021 | Result of appeal procedure: maintenance in amended form | 05.08.2021 | Despatch of the decision of the Board of Appeal | 27.11.2017 | Date of oral proceedings | 16.04.2018 | Minutes of the oral proceedings despatched | 18.06.2021 | Date of oral proceedings | Fees paid | Renewal fee | 09.02.2007 | Renewal fee patent year 03 | 14.07.2008 | Renewal fee patent year 04 | 10.07.2009 | Renewal fee patent year 05 | 14.07.2010 | Renewal fee patent year 06 | 01.08.2011 | Renewal fee patent year 07 | 31.07.2012 | Renewal fee patent year 08 | 31.07.2013 | Renewal fee patent year 09 | 31.07.2014 | Renewal fee patent year 10 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | BG | 25.02.2015 | CY | 25.02.2015 | EE | 25.02.2015 | LT | 25.02.2015 | LV | 25.02.2015 | MC | 25.02.2015 | SI | 25.02.2015 | SK | 25.02.2015 | IS | 25.06.2015 | LU | 06.07.2015 | [2017/39] |
Former [2016/15] | EE | 25.02.2015 | |
LT | 25.02.2015 | ||
LV | 25.02.2015 | ||
MC | 25.02.2015 | ||
SI | 25.02.2015 | ||
SK | 25.02.2015 | ||
IS | 25.06.2015 | ||
LU | 06.07.2015 | ||
Former [2016/13] | EE | 25.02.2015 | |
LT | 25.02.2015 | ||
LV | 25.02.2015 | ||
MC | 25.02.2015 | ||
SI | 25.02.2015 | ||
SK | 25.02.2015 | ||
IS | 25.06.2015 | ||
Former [2016/12] | EE | 25.02.2015 | |
LT | 25.02.2015 | ||
LV | 25.02.2015 | ||
SI | 25.02.2015 | ||
SK | 25.02.2015 | ||
IS | 25.06.2015 | ||
Former [2015/49] | EE | 25.02.2015 | |
LT | 25.02.2015 | ||
LV | 25.02.2015 | ||
SK | 25.02.2015 | ||
IS | 25.06.2015 | ||
Former [2015/39] | LT | 25.02.2015 | |
LV | 25.02.2015 | ||
IS | 25.06.2015 | ||
Former [2015/38] | LT | 25.02.2015 | |
IS | 25.06.2015 | ||
Former [2015/35] | LT | 25.02.2015 | Cited in | International search | [X]US2003118598 (HUNT TERRENCE J [US]); | [X]WO2004006954 (ALLERGAN INC [US], et al); | [X]US2004033241 (DONOVAN STEPHEN [US]); | [X]WO2004043430 (ALLERGAN INC [US], et al); | [E]WO2006013357 (IPSEN LTD [GB], et al); | [E]WO2006013370 (IPSEN LTD [GB], et al) | by applicant | WO9611699 | US5512547 | WO9735604 | US5756468 | WO0158472 | Opposition | WO9937326 | WO0158472 | US2003118598 | US2003138437 | WO2005007185 |